To Reverse ENDocrine Resistance Trial - PD 0332991 Monotherapy vs PD 0332991 in Combination With the Endocrine Therapy
Status:
Completed
Trial end date:
2017-02-09
Target enrollment:
Participant gender:
Summary
This study aims to assess the activity of PD0332991 in monotherapy and in combination with
the endocrine therapy (anastrozole, letrozole, exemestane or fulvestrant) on which the
patient has progressed in the previous line for advanced breast cancer in order to reverse
endocrine resistance.